• About us
• Contact

Advertisement

Organisation › Details

Pfizer (Group)

At Pfizer (NYSE: PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. *

 

	Industry	pharmaceutical
	Region	New York, NY
	Country	United States (USA)
	Street	235 East 42nd Street
	City	10017 New York, NY
	Tel	+1-212-733-2323
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	48,613,000,000 (revenue, consolidated (2007) 2007-12-31)
	Profit	8,298,000,000 (2007-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Pfizer (Group)

• [1] Organon & Co.. (9/3/24). "Press Release: Organon Appoints Daniel Karp as Executive Vice President, Corporate Development". Jersey City, NJ....
• [2] BioNTech SE. (8/22/24). "Press Release: Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine". New York, NY & Mainz....
• [3] BioNTech SE. (8/16/24). "Press Release: Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age". New York, NY & Mainz....
• [4] BioNTech SE. (8/5/24). "Press Release: BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update". Mainz....
• [5] Pfizer Inc.. (4/26/24). "Press Release: U.S. FDA Approves Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B". New York, NY....
• [6] Mission Therapeutics Ltd.. (3/14/24). "Press Release: Mission Therapeutics Raises £25.2 Million to Progress Clinical Candidates in the Area of Mitophagy". Cambridge....
• [7] AstraZeneca plc. (9/20/23). "Press Release: Alexion Completes Purchase and Licence Agreement for Early-stage Rare Disease Gene Therapy Portfolio from Pfizer"....
• [8] CureVac N.V.. (5/19/23). "Press Release: CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech". Tübingen....
• [9] BioNTech AG. (3/14/23). "Press Release: Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years". New York & Mainz....
• [10] Seagen Inc.. (3/13/23). "Press Release: Pfizer Invests $43 Billion to Battle Cancer. Pfizer to Acquire Seagen for $229 per Seagen Share in Cash". New York, NY & Bothell, WA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.